NCT01224977
Unknown
Not Applicable
Development and Validation of a Sputum Biomarker mRNA Panel for the Diagnostic Work-up of Asthma 4.
Overview
- Phase
- Not Applicable
- Intervention
- azithromycin
- Conditions
- Asthmatic Patients
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
- Enrollment
- 20
- Locations
- 1
- Primary Endpoint
- sputum cytokine mRNA
- Last Updated
- 7 years ago
Overview
Brief Summary
The main objectives of the study are:
- To unravel the importance of molecular phenotyping in predicting the response to antimicrobial therapy with potential anti-inflammatory potency
The investigators have developed a non-invasive technique based on mRNA analysis of induced sputum that enables us to study airway inflammation in detail. This technique forms the basis for our current project based on the following hypotheses:
- Different molecular asthma phenotypes exist: a Th2 phenotype and a non Th2 phenotype as reported by Woodruff and colleagues (Woodruff PG et al). Sputum mRNA cytokine levels can be used to diagnose Th2 asthma and discriminate this from non-Th2 asthma.
- Based on our previous research and preliminary data that non-Th2 asthma can be further divided in Th17 asthma and Th1+Th2 asthma; besides these, a fourth group without Th2, Th17 or Th1 characteristics also exist.
- These subgroups have different responses to anti-microbial therapy with potential anti-inflammatory potency (macrolides).
Investigators
Dominque Bullens
prof. dr.
Universitaire Ziekenhuizen KU Leuven
Eligibility Criteria
Inclusion Criteria
- •severe asthmatics (GINA step 4 or step 5 (without anti-IgE))
Exclusion Criteria
- •viral/fungal/bacterial infection +fever (\<1 month)
- •asthma exacerbation (\<3 months)
- •other respiratory disease (CF, ciliary dyskinesia,bronchiectasis)
Arms & Interventions
azithromycin
Intervention: azithromycin
Outcomes
Primary Outcomes
sputum cytokine mRNA
Time Frame: 3 months
Secondary Outcomes
- responsiveness to the medication(3 months)
Study Sites (1)
Loading locations...
Similar Trials
Terminated
Not Applicable
Development and Validation of a Sputum Biomarker mRNA Panel for the Diagnostic Work-up of Asthma 3Asthmatic PatientsNCT01224964Universitaire Ziekenhuizen KU Leuven1
Unknown
Not Applicable
Development and Validation of a Sputum Biomarker mRNA Panel for the Diagnostic Work-up of Asthma 2AsthmaNCT01224951Universitaire Ziekenhuizen KU Leuven40
Not yet recruiting
Not Applicable
Prospective Study for Molecular Biomarkers and Spatial Transcriptomics of Nasopharyngeal CarcinomaNCT05912582Jiangsu Cancer Institute & Hospital60
Active, not recruiting
Not Applicable
Novel Serum Biomarkers for Identifying Plaque Erosion in ACS and Predicting PrognosisPlaque RuptureAcute Coronary SyndromesNCT06763835Xuebo Liu301
Completed
Not Applicable
Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic ProfileMultiple MyelomaNCT01454297Multiple Myeloma Research Foundation1,154